Navigation Links
Pradaxa® (dabigatran etexilate mesylate) Capsules Gains Preferred Formulary Status with AARP®, Nation's Largest Provider of Medicare Part D Coverage
Date:5/19/2011

RIDGEFIELD, Conn., May 19, 2011 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that Pradaxa® (dabigatran etexilate mesylate) capsules has received preferred Tier 2 formulary status with all AARP Medicare Part D plans through its pharmacy benefits manager, Prescription Solutions®.  The AARP plans, which include AARP Medicare Rx and AARP MedicareComplete from Secure Horizons, provide prescription drug access to nearly 6.8 million Americans and represent the largest provider of Medicare Part D coverage in the U.S.  The U.S. Food and Drug Administration (FDA) approved PRADAXA in October 2010 to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF).(1)

More than 25 million Americans are enrolled in a Medicare Part D program, which provides prescription drug coverage for Medicare beneficiaries.  An estimated 2.3 million Americans are living with atrial fibrillation (AFib)(2) and approximately 82 percent are age 65 or older.(2)  A large managed care database study showed that NVAF represents roughly 95 percent of all AFib cases in the U.S.(2)  Atrial fibrillation increases the risk of stroke nearly five times(3) and is associated with up to 15 percent of all strokes in the U.S.(3)

"The addition of PRADAXA to the nation's largest Part D plans helps ensure many more NVAF patients have access to this important medication, which, in a clinical study, has been shown to significantly reduce the risk of stroke compared to warfarin," said Wa'el Hashad, vice president, cardiovascular and metabolic disorders marketing, Boehringer Ingelheim Pharmaceuticals, Inc.  "PRADAXA is now on formulary with AARP, Medco, Express Scripts and several more of the nation's largest managed care providers."

Seven months after FDA approval, PRADAXA is available at the lowest branded co-pay level on formularies that insure more than 45 percen
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Data Published in The Lancet Compare Dabigatran Etexilate to Dose-Adjusted Warfarin Across RE-LY® Trial Centers
2. FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents
3. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
4. Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
5. New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)
6. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
7. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
8. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting
11. Mylan Launches First Generic Version of Amrix® Capsules
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Multiple Sclerosis Drugs Market 2014-2018" ... is a chronic, inflammatory medical condition that results in ... damaged because of an abnormal response by the immune ... (CNS). It is a potentially debilitating disease in which ...
(Date:8/29/2014)...  Abaxis, Inc. (NasdaqGS: ABAX ), a ... to the medical, research and veterinary markets, announced today ... Officer, will present at the CL King 12 th ... 9, 2014 at 12:30 p.m. ET. The conference will ... New York City . ...
(Date:8/29/2014)... and MENLO PARK, Calif. ... Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today ... financial statements.  The Company recently changed its fiscal year ... application to list its common stock on a national ... DelMar,s financial statements as filed with the United States ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 2DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 3DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 4DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments 5
... 5, 2011 Ridge Diagnostics, Inc., a neurodiagnostic ... the 6th Annual Neurotech Investing and Partnering Conference to be ... on May 9th and 10th.   Ms. Williams, ... entitled "Next Generation Psychiatry" lead by Dr. Manuel Lopez-Figueroa, Vice ...
... Taking the right dose is vital to ensuring that ... any harm. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... droppers, or syringes designed to measure the proper dose. But ... there have been accidental overdoses. Find out how ...
Cached Medicine Technology:Ridge Diagnostics, Inc. CEO to Speak at Neurotech Investing and Partnering Conference 2
(Date:8/30/2014)... Seattle, WA (PRWEB) August 30, 2014 One ... of this era is the gluten-free diet. Originally meant for ... has become a catchall for people who are looking to ... gluten. However, not only is this kind of information erroneous, ... of health problems because of a drastic change in ...
(Date:8/30/2014)... August 30, 2014 August 28th, 2014: ... pain in our society and the toll that takes ... it’s vital that continuing education for physical therapists addresses ... help physical therapists help others, Hands-On Seminars is offering ... , Three learning styles are available to fit ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 When a prominent ... ensue, as happened on Wednesday, August 27th, when news began ... on JPMorgan Chase & Co and at least one ... is actually investigating attacks on seven prominent banks , ... may be affected, and the buzz quickly goes viral. ...
(Date:8/30/2014)... August 30, 2014 As 500 Zoloft lawsuits ... when give to pregnant mothers, Wright & Schulte LLC recently ... M. Rufe. The remand in the Zoloft lawsuits ... 18 states and are involved in one SSRI lawsuit ... have their Zoloft birth defect lawsuit sent back to the ...
(Date:8/30/2014)... August 30, 2014 Barton Associates, an ... locum tenens company , announces a new office location ... Barton Associates is headquartered in Peabody, MA, with additional ... Austin, TX; and Jupiter, FL. , Barton Associates made ... the physician shortage crisis affecting the United States, a ...
Breaking Medicine News(10 mins):Health News:“What is Gluten: Three Things You Need to Know Before Adopting a Gluten-Free Diet” Reveals What Readers Need to Know About the Benefits of a Strict Gluten Diet - Vinamy 2Health News:Leader in Manual Therapy Continuing Education Makes it Easier for Physical Therapists to Improve Results on Patients 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 2Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 3Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 4Health News:Big Name Bank Hacks Highlight the Importance of Regular Testing and Effective Emergency Response 5Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5Health News:Barton Associates to Open a New Office Location in Keene, NH 2
... Colonic lipomas have been found in related literature. One ... 14 issue of the World Journal of Gastroenterology because ... discussed age and sex factors, clinical and histopathological findings, ... and previously available literature. , The article reported ...
... Food and Drug Administration (FDA) has awarded the ... $1 million Orphan Products Development grant to study ... skin or internal organs., The unique, interdisciplinary, and ... Drolet, M.D., professor of dermatology and pediatrics, at ...
... Researchers at the Board of Governors Gene Therapeutics Research ... first time that it is possible to sustain therapeutic ... to a year, even in the presence of an ... humans. , The researchers demonstrated in an animal ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... long-term outcomes, researchers say , THURSDAY, Oct. 25 (HealthDay News) ... peptide (ANP) can lessen cardiac injuries after heart attack and ... a Japanese study in this week,s issue of The ... damaged heart muscle (infarct) and lessened what,s known as "reperfusion ...
... 26 AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Inc Webcast, When: November 1, 2007 @ 8:30 AM ... over the Internet -- Simply log on to the web at ... Contact: Lisa Gould of AMICAS, Inc, 617-779-7892. If you ...
Cached Medicine News:Health News:The largest colonic lipoma to date 2Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2
This compact, easy-to-operate analyzer delivers basic blood gas, ISEs with direct measured total hemoglobin and saturated oxygen. Use it as a cost effective backup for the central lab or for remote p...
... performance and rapid, small volume sample ... rotor. DiscoveryTMM120 SE processes sample sizes ... with a small floor footprint, brushless ... imbalance detection, thermo-electric cooling, and automatic ...
... Efficiency, versatility, and environmental ... the Optima LE-80 K Ultracentrifuge ... Coulters innovative Optima centrifugation technology, ... to cost effectively provide advanced ...
... small-volume samples. With the ability to provide ... (fat particles in lipemic samples), the Airfuge ... Lipemic samples can be cleaned in 10 ... The easy-to-operate tabletop centrifuge: Reaches top speed ...
Medicine Products: